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Abstract: More than 25 million lives have been claimed by AIDS and 33.2 million people are estimated to have HIV, the 
majority of which are living in the underdeveloped countries. Failed tests on vaccines, virucides and complete virus eradi-
cation have caused scientists to refocus on the basic questions of what makes an effective HIV immune response. The 
"gloom" over disappointing research results on vaccine development and virucides "threatens to overshadow more posi-
tive" HIV/AIDS-related news, such as findings that male circumcision might reduce the likelihood of HIV transmission 
and that giving antiretroviral drugs to "high-risk" HIV-negative people (pre-exposure prophylaxis)  could help protect 
them from infection. Something like pre-exposure prophylaxis has a good chance of becoming available before we have a 
100% efficacious vaccine. The future in the field of HIV/AIDS will be much brighter if global research is appropriately 
coordinated and sufficient funds are available. 
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INTRODUCTION 
  To date, more than 25 million lives have been claimed by 
AIDS and 33.2 million people are estimated to have HIV, the 
majority of which are living in the underdeveloped countries. 
Failed tests on vaccines, microbicides and virus eradication 
have caused scientists to refocus on the basic questions of 
what  makes  an  effective  HIV  immune  response  and  how 
scientists can create neutralizing antibodies that block HIV 
infection [1]. Disappointing news in the field of HIV vaccine 
research came last year when Merck halted clinical trials of 
an experimental vaccine over safety concerns. The "gloom" 
over disappointing research results "threatens to overshadow 
more positive" HIV/AIDS-related news, such as findings that 
male  circumcision  might  reduce  the  likelihood  of  HIV 
transmission  and  that  giving  antiretroviral  drugs  to  "high-
risk" HIV-negative people could help protect them from in-
fection, a concept that is referred to as pre-exposure prophy-
laxis  [2].  Something  like  pre-exposure  prophylaxis  has  a 
good chance of becoming available before we have a 100% 
efficacious vaccine. 
  Since the beginning of the AIDS epidemic, scientists and 
clinicians were working with a disease that was not treatable 
at all, and the majority of patients died relatively quickly. In 
the  nineties  and due  to  better  recognition  of  how  HIV 
spreads  and  to  new  medications  developed  for  treatments, 
the disease became more treatable. The next goal is a cure, in 
other words “complete viral eradication”, having the ability  
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to remove the virus from the body or to suppress it to the 
point where it can no longer cause any damage. This goal is 
reachable  as  the  progress  we  are  making  against  HIV  is 
much larger than in other comparable serious diseases. Cur-
rently medications are better than ever at treating AIDS pa-
tients and possibly even healing them. 
  In this article, we will discuss briefly the current situation 
with regard to vaccines, microbicides (virucides) and drugs 
against HIV/AIDS and the future expectation in these impor-
tant areas. 
VACCINES 
  Recently  major  vaccination  studies  have  been  stopped 
and we, unfortunately, do not expect to find a vaccine in the 
very near future [3]. However, there are other possibilities to 
prevent new infections. We know, for example, that people 
who do not have detectable viruses because they are success-
fully treated, hardly ever infect others. These individuals no 
longer pose a danger of infecting others as far as new infec-
tions  are  concerned.  However,  the  AIDS  pandemic  would 
only be defeated by a preventative vaccine, rather than treat-
ing people who are already infected. 
  Out of the 50 candidates that have been evaluated among 
humans, only two vaccines have made it through all three 
phases of trials, and both were rejected as quite ineffective
 
[3,4]. Most recently, one major vaccine trial was halted after 
early results showed that it appeared to place volunteers at 
greater risk of HIV infection [3,4]. Another vaccine in plan-
ning  phases,  involving  tests  among  8,500  individuals  was 
found to be largely ineffective [3,4]. Despite these failures, 
about 30 vaccines remain in the pipeline, looking at different 
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  Although HIV vaccine development is difficult, its bene-
fits could be tremendous [5]. The challenges are huge, but 
with no doubt that we will live in a world without HIV some 
day. Vaccine researchers need to be unafraid to fail. We need 
to examine carefully why some vaccines have worked, and 
try  and  dissect  why  they  have  worked.  More  emphasis 
should  be  put  on  studying  human  immune  responses  and 
taking into consideration successful vaccines for other dis-
eases such as influenza, yellow fever, and hepatitis-B as pos-
sibly useful models. 
VIRUCIDES 
  Virucides are microbicidal agents that are able to destroy 
virus particles on contact. They differ from antivirals in that 
they are designed to act directly and rapidly by lysing viral 
membranes  on  contact  [6,  7].  Recently  attention  has  been 
directed towards the possible use of these agents as a preven-
tive factor against the sexual transmission of HIV infection. 
Sexual intercourse is an important route of HIV transmission 
and the need for an agent that can be used safely and effec-
tively by women before sexual intercourse and without the 
need  for  agreement  from  the  male  partner  demands  more 
research from scientists. For example, the spermicidal non-
oxynol-9, a non-ionic surfactant, possesses anti-HIV-1 activ-
ity and has been used experimentally as a means of reducing 
the risk of viral transmission [8]. However, this virucide has 
a  damaging  effect  on  the  epithelial  linings  of  the  female 
genital tract, and is believed to enhance the susceptibility to 
HIV infection rather than preventing infection [7]. Therefore, 
new agents that possess virucidal activity without cytotoxic-
ity on normal cells are required. Among many compounds 
being tested, bile salts with high surfactant activity may rep-
resent a class of compounds that can be used as virucides 
against HIV [6]. Their ability to inactivate high tittered HIV 
gives them the unique property of being used as biological 
disinfectants as well as virucide compounds. 
  Researchers’ believed virucides delivered in a gel appli-
cator, vaginal ring or capsule, could be a godsend to African 
women facing the threat of coercive sex by an infected part-
ner. There have been nine fully-completed or halted trials of 
microbicide candidates, one of which showed that the proto-
type actually boosted the risk of infection by causing vaginal 
lesions  that  helped  the  virus  to  enter  the  bloodstream  [8]. 
The  new  tack  is  to  look  at  a  gel  that  incorporates  virus-
killing drugs that are already tried-and-tested among people 
with HIV. At least five gels in this category are in the early 
stages of trials and despite past failures, there is a true cause 
for optimism in this field. 
  After the disappointing results from all vaccine efficacy 
trials conducted to date, the field of microbicides (virucides) 
research now faces many challenges. New promising strate-
gies  are  now  available.  However,  proper  coordination  be-
tween researchers need to be addressed to advance the next 
generations of candidates into clinical trials, and the use of 
appropriate animal models in this process will be critical [9]. 
DRUGS 
  The clinical course of AIDS was drastically changed in 
the  nineties  with  the  advent  of  highly  active  antiretroviral 
therapy  (HAART).  In  the  majority  of  AIDS  patients, 
HAART leads to sustained reductions in HIV-1 replication, 
rise in CD4+ T-cell count, and concomitant immune recon-
stitution, resulting in significant reductions in morbidity and 
mortality.  These  benefits,  however,  have  been  achieved  at 
the cost of considerable drug toxicity and monetary expense. 
It is well accepted that HAART alone will not cure HIV-1 
infection because of the existence of persistent viral reser-
voirs, which ultimately rekindle viral replication once ther-
apy  is  stopped  [10].  Consequently,  any  attempts  at  viral 
eradication will depend on the implementation of therapeutic 
strategies  to  specifically  target  and  clear  these  reservoirs. 
The best characterized reservoir to date is the pool of latently 
infected memory CD4+ T cells. 
  Using antiretroviral drugs as a "pre-exposure" prevention 
is another strategy being currently investigated. The idea is 
to  have  people  at  risk  from  infection  take  one  drug,  or  a 
combination of more than one, before having sex to prevent 
infection. However, this may help the virus to mutate; in the 
same way that misusage of antibiotics can lead to drug resis-
tance. 
THE FUTURE 
  Despite the intensive research conducted to uncover the 
pathogenesis  of  HIV/AIDS,  the  whole  picture  of  AIDS 
pathogenesis is still not clear. During HIV infection, there is 
a window period that we do not know much about. This is 
referred to as the window of vulnerability. This can become 
a  window  of  opportunity  because  in  that  very  short 
timeframe with the bursts of viremia and the establishment 
of a reservoir with a latent component occur. It is in that very 
small timeframe that our success or failure with vaccines as 
well with our ability to ultimately control, perhaps even cure 
HIV will rest. Virus reservoir is established literally within 
days of acute infection. Therefore,  this window of vulner-
ability and opportunity is short. A recent paper showed that 
not only a reservoir is formed early, but byproducts of CD4 
positive T-cell deaths increase significantly within days and 
are capable of suppressing the human immune response to 
the virus [11]. So, we have a double whammy. We have a 
reservoir that almost immediately formed and we have prod-
ucts of the death of cells suppressing the immune response 
that would hopefully prevent the establishment of that reser-
voir. Therefore, future research should aim at reversing these 
processes. 
  Functional  genomic  screening,  particularly  large  scale, 
small inhibitory RNA screening will in the future open up 
avenues  of  new  targets.  Selective  small  inhibitory  RNAs, 
over  270  proteins  were  identified,  only  36  of  which  have 
been  previously  implicated  in  HIV  replication.  There  are 
scores and scores of intercellular targets that can be used in a 
new pipe line of interventions [12]. These anti-sense inhibi-
tors hold promise as potential new agents to induce the latent 
reservoir  without  resulting  in  global  cellular  activation. 
However, anti-sense therapy is limited by its poor stability in 
the body and limited intracellular uptake and issues regard-
ing  in  vivo  delivery  remain.  As  our  understanding  of  the 
mechanisms  controlling  HIV-1  latency  grows,  additional 
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  There is an urgent need to broaden research and to an-
swer fundamental questions in HIV/AIDS pathogenesis and 
vaccine development through laboratories, the use of non-
human primate, and clinical research. In addition, it is impor-
tant to attract and retain young researchers in the area of HIV 
pathogenesis, vaccine development and the discovery of new 
therapeutic agents. 
CONCLUSION 
  Although  results  of  HIV  vaccine  research  have  been 
"unrelentingly negative" in recent years, scientists should not 
give up and still should increase efforts to develop a vaccine. 
Big  investments  for  the  future  are  needed  not  only  in  the 
basic science of HIV prevention, but also in clinical trials for 
the search for an effective HIV vaccine.  Collaboration for 
vaccine development, new virucides and new drugs need to 
be increased but avoiding wasted or duplicated efforts. Pre-
exposure prophylaxis should be investigated in parallel with 
research for vaccines, virucides and new drugs. The future, 
in the field of HIV/AIDS, will be much brighter if global 
research is appropriately coordinated with appropriate fund-
ing being available. 
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